The Phase 3 CLEAR Trial: Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

home / investigator-perspectives / the-phase-3-clear-trial-lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell-carc

Robert J. Motzer, MD, gives a comprehensive background and analysis on the phase 3 CLEAR trial, which investigated lenvatinib plus pembrolizumab or everolimus versus sunitinib in the treatment of advanced renal cell carcinoma.

EP. 1: Current Therapies for Advanced RCC: Options and Challenges

June 29th 2021

Robert J. Motzer, MD, gives a background on the current first-line therapy options for advanced renal cell carcinoma, including challenges and unmet needs.

Watch

EP. 2: Key Efficacy and Safety Findings from the CLEAR Trial

June 29th 2021

Dr Robert J. Motzer introduces data from the phase 3 CLEAR trial, which investigated lenvatinib plus pembrolizumab or everolimus for the treatment of advanced renal cell carcinoma.

Watch

EP. 3: Impact of the CLEAR Trial on Clinical Practice

June 29th 2021

An expert explains the impact of the CLEAR trial on clinical practice and reviews NCCN guidelines for the management of advanced renal cell carcinoma.

Watch

EP. 4: Updates on CLEAR from ASCO 2021

June 29th 2021

Dr Motzer discusses data from the CLEAR trial that were presented at ASCO 2021.

Watch

EP. 5: The Future of Therapy for Advanced RCC

June 29th 2021

Robert J. Motzer, MD, shares his insights on the future of treatment for advanced renal cell carcinoma.

Watch